Skip to content

Study · Non-randomized trial · 2021

3 results

Efficacy and safety of Cerebrolysin after futile recanalisation therapy in patients with severe stroke.

Poljakovic Z, Supe S, Ljevak J, Starcevic K, Peric I, Blazevic N, Krbot-Skoric M, Jovanovic I, Ozretic D

Clinical neurology and neurosurgery18 Jun 2021Cited by 22 (Europe PMC)

PMID34214867 (opens in a new tab)DOI10.1016/j.clineuro.2021.106767 (opens in a new tab)PepBankPUB-34214867
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In severe stroke patients after recanalisation, haemorrhagic transition was significantly lower with Cerebrolysin than control.

    In plain wordsIn severe stroke patients, haemorrhagic transition was significantly lower with Cerebrolysin than control.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseHaemorrhagic transition
    Study

    n: not reported in source

    Comparator
    Control group
    Analysis
    Secondary
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    We found a statistically significant difference considering haemorrhagic transition and mortality rate in favour of the Cerebrolysin group.
    2 context sentences
    Summary · context
    After recanalisation therapy and not later than 24 h after symptoms onset, patients with initial NIHSS of ≥ 8 were assigned to the investigational and control group.
    Summary · context
    The investigational group received intravenous Cerebrolysin as add-on therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In severe stroke patients after recanalisation, Cerebrolysin showed no detectable mRS difference versus control despite descriptive superiority.

    In plain wordsIn severe stroke patients, Cerebrolysin showed no detectable disability difference versus control despite descriptive superiority.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeModified Rankin scale
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    No difference could be detected between the two groups in the mRS scale though the Cerebrolysin group showed descriptive superiority over the control group.
    2 context sentences
    Summary · context
    After recanalisation therapy and not later than 24 h after symptoms onset, patients with initial NIHSS of ≥ 8 were assigned to the investigational and control group.
    Summary · context
    The investigational group received intravenous Cerebrolysin as add-on therapy.
  3. 03HumanNon-randomized trialSafety outcome

    In severe stroke patients after recanalisation, mortality was significantly lower with Cerebrolysin than control.

    In plain wordsIn severe stroke patients, mortality was significantly lower with Cerebrolysin than control.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMortality
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Mortality · Nervous system and cognition
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    We found a statistically significant difference considering haemorrhagic transition and mortality rate in favour of the Cerebrolysin group.
    2 context sentences
    Summary · context
    After recanalisation therapy and not later than 24 h after symptoms onset, patients with initial NIHSS of ≥ 8 were assigned to the investigational and control group.
    Summary · context
    The investigational group received intravenous Cerebrolysin as add-on therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · source ClinicalTrials.gov (opens in a new tab)

Status unknownEarly phase 1NCT06489925

Cerebrolysin as an Add-On Therapy to Standard Treatment of Basilar Artery Occlusion

University Hospital Sestre Milosrdnicen = 20est. Jul 2024 to est. May 2026

Basilar Artery Occlusion · Posterior Circulation Brain Infarction

Trial pageClinicalTrials.govUpdated 9 Jul 2024
Status unknownPhase 4NCT06078215

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

Poznan University of Medical Sciencesn = 35010 Jan 2023 to est. 31 Mar 2025

Acute Ischemic Stroke

Trial pageClinicalTrials.govUpdated 13 Oct 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.